Pt has respiratory acidosis (low blood pH) due to his asthma exacerbation. What will the nurse expect to see?

Choice A reason: ARBs do not affect the LDL cholesterol levels. They lower the blood pressure by blocking the action of angiotensin II, which is a hormone that causes vasoconstriction and sodium retention. Statins are the drugs that lower the LDL cholesterol levels.

Choice B reason: ARBs do not cause weight loss of more than 2 pounds/week. They lower the blood pressure by blocking the action of angiotensin II, which is a hormone that causes vasoconstriction and sodium retention. Diuretics are the drugs that cause weight loss by increasing the urine output and reducing the fluid volume.

Choice C reason: ARBs do not increase the urinary output. They lower the blood pressure by blocking the action of angiotensin II, which is a hormone that causes vasoconstriction and sodium retention. Diuretics are the drugs that increase the urinary output by inhibiting the reabsorption of sodium and water in the kidneys.

Choice D reason: ARBs lower the blood pressure by blocking the action of angiotensin II, which is a hormone that causes vasoconstriction and sodium retention. Therefore, a nursing assessment that confirms that the ARB that a patient is taking is effective is a decrease in the blood pressure. This is the correct statement that describes the expected outcome of ARBs.

Choice A reason: This is not a correct statement. LABAs stand for long-acting beta2-agonists, which are a class of medications that relax the smooth muscles of the airways and improve the airflow in patients with asthma or COPD. However, LABAs do not reduce the risk of asthma-related deaths, and may even increase it if used alone without an inhaled glucocorticoid, which is a type of anti-inflammatory medication.

Choice B reason: This is not a correct statement. LABAs cannot be used on an as-needed basis to treat symptoms, as they have a slow onset of action and a long duration of effect. LABAs are meant to be used as a maintenance therapy to prevent asthma exacerbations, not to relieve acute symptoms. For quick relief of symptoms, patients should use a short-acting beta2-agonist, such as albuterol or salbutamol.

Choice C reason: This is not a correct statement. LABAs are not safer than short-acting beta2 agonists, as they have similar side effects, such as tachycardia, tremors, and hypokalemia. LABAs also have a black box warning that they may increase the risk of asthma-related deaths if used without an inhaled glucocorticoid.

Choice D reason: This is the correct statement. LABAs should be combined with an inhaled glucocorticoid, as this combination has been shown to improve the asthma control, reduce the frequency and severity of exacerbations, and decrease the inflammation and airway hyperresponsiveness. The inhaled glucocorticoid also reduces the risk of adverse effects and mortality associated with LABAs.